Misplaced Pages

Nibrozetone: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 14:22, 28 December 2024 editIdoghor Melody (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers34,718 editsm clean up, added orphan tagTag: AWB← Previous edit Revision as of 12:18, 1 January 2025 edit undoRodw (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers773,857 editsm Disambiguating links to Hypoxia (link changed to Hypoxia (medical)) using DisamAssist.Next edit →
Line 110: Line 110:
| specific_rotation = | specific_rotation =
}} }}
'''Nibrozetone''' is an ] that is being evaluated by EpicentRx for the treatment of oral ] in ] patients. It is a small molecule that combines direct inhibition of the ] inflammasome, induction of ], and release of ] under ] conditions.<ref name="Oronsky_2023">{{cite journal | vauthors = Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T | title = RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist | journal = Frontiers in Oncology | volume = 13 | issue = | pages = 1204143 | date = 2023 | pmid = 37313460 | pmc = 10258348 | doi = 10.3389/fonc.2023.1204143 | doi-access = free | url = }}</ref><ref name="pmid36920652">{{cite journal | vauthors = Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, Birch NA, O'Sullivan JD, Gordon R | title = A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation | journal = Drugs | volume = 83 | issue = 5 | pages = 389–402 | date = April 2023 | pmid = 36920652 | pmc = 10015535 | doi = 10.1007/s40265-023-01838-z | url = }}</ref> It has received ] designation from the FDA for severe oral mucositis in head and neck cancer patients.<ref>{{cite web | vauthors = Ryan C |title=FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer |url=https://www.onclive.com/view/fda-grants-fast-track-designation-to-rrx-001-for-severe-oral-mucositis-in-head-and-neck-cancer# |website=OncLive |language=en |date=30 March 2023}}</ref> '''Nibrozetone''' is an ] that is being evaluated by EpicentRx for the treatment of oral ] in ] patients. It is a small molecule that combines direct inhibition of the ] inflammasome, induction of ], and release of ] under ] conditions.<ref name="Oronsky_2023">{{cite journal | vauthors = Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T | title = RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist | journal = Frontiers in Oncology | volume = 13 | issue = | pages = 1204143 | date = 2023 | pmid = 37313460 | pmc = 10258348 | doi = 10.3389/fonc.2023.1204143 | doi-access = free | url = }}</ref><ref name="pmid36920652">{{cite journal | vauthors = Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, Birch NA, O'Sullivan JD, Gordon R | title = A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation | journal = Drugs | volume = 83 | issue = 5 | pages = 389–402 | date = April 2023 | pmid = 36920652 | pmc = 10015535 | doi = 10.1007/s40265-023-01838-z | url = }}</ref> It has received ] designation from the FDA for severe oral mucositis in head and neck cancer patients.<ref>{{cite web | vauthors = Ryan C |title=FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer |url=https://www.onclive.com/view/fda-grants-fast-track-designation-to-rrx-001-for-severe-oral-mucositis-in-head-and-neck-cancer# |website=OncLive |language=en |date=30 March 2023}}</ref>


== References == == References ==

Revision as of 12:18, 1 January 2025

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Nibrozetone
Clinical data
Other namesRrx-001
Identifiers
IUPAC name
  • 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC5H6BrN3O5
Molar mass268.023 g·mol
3D model (JSmol)
SMILES
  • C1C(CN1C(=O)CBr)((=O))(=O)
InChI
  • InChI=InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2
  • Key:JODKFOVZURLVTG-UHFFFAOYSA-N

Nibrozetone is an investigational new drug that is being evaluated by EpicentRx for the treatment of oral mucositis in head and neck cancer patients. It is a small molecule that combines direct inhibition of the NLRP3 inflammasome, induction of NRF2, and release of nitric oxide under hypoxic conditions. It has received Fast Track designation from the FDA for severe oral mucositis in head and neck cancer patients.

References

  1. Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T (2023). "RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist". Frontiers in Oncology. 13: 1204143. doi:10.3389/fonc.2023.1204143. PMC 10258348. PMID 37313460.
  2. Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, et al. (April 2023). "A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation". Drugs. 83 (5): 389–402. doi:10.1007/s40265-023-01838-z. PMC 10015535. PMID 36920652.
  3. Ryan C (30 March 2023). "FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer". OncLive.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Nibrozetone: Difference between revisions Add topic